Background: The novel echinocandin CD101 has stability properties amenable to topical formulation for use in the treatment of acute vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC). CD101 has demonstrated potent antifungal activity at pH 7, but assessment of its activity at the physiological pH of the vaginal environment is needed.
Introduction
Vulvovaginal candidiasis (VVC) affects most women at least once in their lifetime. The reported incidence of VVC varies widely between 12.1% and 57.3% and up to 91% in pregnant women, reflecting the lack of reliable, consistent epidemiological data to provide more definitive estimates. The incidence of recurrent VVC (RVVC), i.e. four or more episodes of VVC in 1 year, is even more difficult to evaluate. Nevertheless, the impact and morbidity of VVC and RVVC are well recognized and warrant continued efforts toward improving patient outcomes. 1, 2 Candida albicans is the most common aetiological agent of VVC and RVVC. Non-albicans Candida spp., particularly Candida glabrata, account for 5%-15% of infections and are more prevalent in certain populations (e.g. patients with type 2 diabetes 3 or RVVC 4, 5 ). VVC is commonly treated with azole antifungals, which are fungistatic against Candida spp., are less effective against non-albicans Candida spp. and have lower activity at vaginal pH. 6 Non-albicans Candida spp. also are more likely to be azole resistant and are more difficult to treat. 7, 8 Despite these unmet and emerging needs, there has been no novel class of agents for the treatment of VVC and RVVC for decades.
An optimal new therapeutic for VVC/RVVC would not only have strong activity against all Candida spp. and azole-resistant strains, but also maintain activity at vaginal pH (4-4.5) during VVC infections. 9 Based on their intrinsic potency and efficacy against systemic Candida infections, echinocandins have many apparent advantages over azoles: fungicidal versus fungistatic, broader spectrum of activity against Candida spp., lower prevalence of resistance, fewer drug-drug interactions and better overall safety. [10] [11] [12] However, little work has been done to characterize echinocandin activity at the lower pH of the vaginal environment. 6 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com This is ostensibly because currently available echinocandins are limited to intravenous administration, which is impractical for VVC/ RVVC, and their stability/solubility are major barriers to topical dosage forms. CD101 is a novel echinocandin with demonstrated stability and solubility suitable for topical formulations. 13 The antifungal activity of CD101 is comparable to currently marketed echinocandins against contemporary surveillance isolates 14 as well as against panels enriched for drug-resistant Candida spp. strains. 15 Here CD101 was evaluated against a collection of clinical VVC isolates of Candida spp., including azole-resistant strains, at pH 7 and 4.
Methods

Clinical VVC isolates
Candida strains evaluated in this study were clinical vaginal isolates obtained from the Wayne State University Vaginitis Clinic organism bank. Isolates were obtained from VVC patients under an IRB-approved consent protocol and were anonymized prior to MIC testing. The strain panel was composed of randomly selected C. albicans (n " 60, 10 fluconazole resistant), C. glabrata (n " 21, 11 fluconazole resistant), Candida parapsilosis (n " 14, 7 fluconazole resistant) and Candida tropicalis (n " 13). Isolates were plated on CHROMagar to verify purity and then plates were incubated for 48 h at 37 C. A single colony was subcultured on Sabouraud dextrose agar and incubated for 24 h at 35 C.
Antifungal susceptibility testing
Susceptibility testing was performed according to CLSI broth microdilution guidelines, 16, 17 with the exception that MIC values were read after 24 and 48 h as the lowest drug concentration to exhibit 80% reduction in growth. RPMI 1640 medium (buffered with 0.165 M MOPS) was adjusted to a final pH of 7 with NaOH or pH 4 with HCl. Assay inoculum was achieved by using spectrophotometric inoculum preparation according to CLSI guidelines. 16 This assay involved adding 100 lL of yeast inoculum containing 0.5-2.5 % 10 3 cfu/mL in RPMI 1640 medium to each well. CD101 (Cidara Therapeutics, Inc.) was prepared in 100% DMSO. Comparator agents (fluconazole, itraconazole, caspofungin, micafungin and anidulafungin) were prepared in 100% DMSO according to CLSI guidelines. 17 Quality control (QC) strains Candida krusei ATCC 6258 and C. parapsilosis ATCC 22019 were included in all assays. 
Results
C. tropicalis (n " 13)
CD101 had MIC 90/50 values of 0.125/0.06 mg/L at pH 7 after 24 h, 8-fold more potent than those of caspofungin and 4-to 8-fold less potent than those of micafungin and anidulafungin. At pH 4, the 4-fold decrease in CD101 activity observed for C. albicans and C. glabrata was also observed for C. tropicalis. At pH 4, only two isolates demonstrated fluconazole resistance after 24 h although that increased to eight fluconazole-resistant isolates at 48 h. Although itraconazole MIC values shifted 4-fold from 24 to 48 h, within each timepoint there was no shift between pH 4/7, and MIC values were much lower than for fluconazole.
Discussion
In this study we have demonstrated that CD101 has potent activity against vaginal isolates of Candida spp. comprising the most common causative agents of VVC/RVVC at a clinically relevant pH. Furthermore, due to CD101's intrinsic potency and lack of crossresistance with azoles, CD101 MIC 90 values were lower than those of fluconazole for all four Candida spp. at both timepoints and pH values.
At pH 7, the CD101 MIC 90 data for this VVC isolate panel were consistent with values from predominantly non-vaginal Candida isolates derived from international surveillance studies that were generated using strict M27-A3 50% inhibition endpoint methodology.
14, 18 Overall, CD101 and comparator agents demonstrated minor increases in MIC values at longer incubation times and lower pH. An inverse correlation between MIC values and pH was also observed against a similar collection of Candida spp. VVC isolates for a variety of antifungal drug classes. 6 With the exception of C. parapsilosis, the organisms in this study yielded similar results. MIC shifts at 48 versus 24 h functionally resulted in the transition from susceptible to resistant fluconazole MIC values for many isolates, as documented previously. 19 Not surprisingly, many isolates resistant to fluconazole were also resistant to itraconazole (especially C. glabrata). Another study demonstrated increases in fluconazole MIC values at pH 4 (as well as for clotrimazole and miconazole); however, interestingly, itraconazole had an inverse effect against that collection of vaginal isolates tested. 20 MIC shifts incurred by CD101 at pH 4 (typically 4-fold) are likely inconsequential to efficacy based on the high localized drug concentrations anticipated following topical administration of CD101 (.100 mg/L estimated). 21 In the absence of in vivo data to confirm intravaginal concentrations, MIC analyses using anticipated CD101 topical formulations would be informative, but are precluded as some formulation viscosities are incompatible with CLSI broth-testing methodologies. Although the comparator echinocandins also exhibited minimal shifts at pH 4, 6 their results can only provide within-class context, as these comparators are unviable for topical administration. Future studies investigating the activity of CD101 against echinocandin-resistant Candida isolates at vaginal pH would be informative and their absence is a limitation of this current dataset.
Despite their prevalent use for treatment of VVC/RVVC, the azole drug class is not adequate for infections caused by nonalbicans Candida spp. and azole-resistant C. albicans. From spectrum, potency, mechanism of action and safety perspectives, echinocandins are an attractive option, but the chemical stability of currently available echinocandins has precluded topical administration and consideration as treatment of VVC/RVVC. Correspondingly, very little work has been done to characterize the antifungal activity of echinocandins at low pH. The enhanced stability properties of CD101 are highly differentiated and may enable topical administration. The susceptibility data generated in this study demonstrate that CD101 retains potent activity against VVC isolates under conditions relevant to the vaginal environment. These results support the continued clinical development of CD101 as the first topical echinocandin for the treatment of VVC/RVVC. 
